These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21729684)

  • 1. Prolonged remission of fulminant castrate-resistant prostate cancer: a case report.
    Bilen MA; General R; Tu SM
    Clin Genitourin Cancer; 2011 Dec; 9(2):133-6. PubMed ID: 21729684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer.
    Shamash J; Stebbing J; Sweeney C; Sonpavde G; Harland S; Dawkins G; Brock C; Abelman W; Wilson P; Sanitt A; Oliver T; Powles T
    Cancer; 2010 Aug; 116(15):3595-602. PubMed ID: 20564115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report: responses to cabazitaxel in metastatic castration-resistant prostate cancer after extensive docetaxel treatment.
    Guancial EA; Taplin ME
    Clin Genitourin Cancer; 2011 Dec; 9(2):130-2. PubMed ID: 21816687
    [No Abstract]   [Full Text] [Related]  

  • 4. Experiences with estramustine phosphate (Estracyt, Emcyt) in prostate cancer.
    Murphy GP; Slack NH; Mittelman A
    Semin Oncol; 1983 Sep; 10(3 Suppl 3):34-42. PubMed ID: 6364365
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful treatment of poor prognostic patients with advanced prostatic carcinoma with the association of diethylstilbestrol and cyclophosphamide.
    Germá Lluch JR; Marcuello Gaspar E; de Andrés Basauri L; López Pousa A; López López JJ
    Rev Esp Oncol; 1982; 29(2):317-24. PubMed ID: 7188232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma.
    Daliani DD; Assikis V; Tu SM; Papandreou CN; Pagliaro LC; Holtkamp T; Wang X; Thall PF; Logothetis CJ
    Cancer; 2003 Feb; 97(3):561-7. PubMed ID: 12548597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Case of malignant lymphoma of the prostate complicated with prostate adenocarcinoma].
    Chin K; Fujimura M; Sekit N; Mikami K; Kamijima S; Suzuki H; Ichikawa T
    Nihon Hinyokika Gakkai Zasshi; 2009 Nov; 100(7):698-702. PubMed ID: 19999135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of stage D2 prostatic carcinoma with combined gonadal and adrenal suppression in a 60-year-old man.
    Gross KM; Bremner WJ
    Am J Med; 1987 Aug; 83(2):359-61. PubMed ID: 2956882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A case of prostate cancer treated with combined androgen-blockade].
    Kurita M; Kato Y; Tamura Y; Suzuki K; Yamanaka H
    Gan To Kagaku Ryoho; 2000 Feb; 27(2):307-10. PubMed ID: 10700907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
    Koutsilieris M; Bogdanos J; Milathianakis C; Dimopoulos P; Dimopoulos T; Karamanolakis D; Halapas A; Tenta R; Katopodis H; Papageorgiou E; Pitulis N; Pissimissis N; Lembessis P; Sourla A
    Expert Opin Investig Drugs; 2006 Jul; 15(7):795-804. PubMed ID: 16787142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical evaluation of the usefulness of endocrine therapy combined with chemotherapy as an initial treatment of prostatic cancer].
    Matsuoka K; Yoshitake N; Noguti M; Tanaka H; Noda S; Eto K
    Nihon Hinyokika Gakkai Zasshi; 1988 Sep; 79(9):1559-66. PubMed ID: 3244222
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic castrate-resistant prostate cancer, dawn of a new age of management.
    Nemr EG
    BJU Int; 2013 Mar; 111(3):E9-E10. PubMed ID: 23444940
    [No Abstract]   [Full Text] [Related]  

  • 14. [Somatostatin analogs in the combined treatment of patients with hormone-resistant prostate cancer].
    Kaprin AD; Gafanov PA; Fastovets SV
    Vopr Onkol; 2009; 55(4):474-6. PubMed ID: 19947374
    [No Abstract]   [Full Text] [Related]  

  • 15. Small cell carcinoma of the prostate.
    Sule-Suso J; Brunt AM
    Br J Radiol; 1992 Aug; 65(776):726-8. PubMed ID: 1382791
    [No Abstract]   [Full Text] [Related]  

  • 16. [A case report of prostate cancer resistant to endocrine therapy successfully treated with intra-arterial chemotherapy].
    Mima H; Asano M; Ozeki S; Ehara H; Takahashi Y; Ishihara S; Deguchi T; Kuriyama M; Ban Y; Kawada Y
    Gan To Kagaku Ryoho; 1995 Sep; 22(11):1694-6. PubMed ID: 7574795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial treatment of prostatic cancer by endocrine measures and cytotoxic drugs.
    Tunn UW; Goldschmidt AJ; Peter K; Becker M
    Prog Clin Biol Res; 1990; 359():165-76; discussion 177-80. PubMed ID: 2149458
    [No Abstract]   [Full Text] [Related]  

  • 18. Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.
    Pienta KJ;
    Urology; 2003 Dec; 62 Suppl 1():95-101. PubMed ID: 14747047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neuroendocrine differentiation in adenocarcinoma of prostate during combined androgen blockade therapy: a case report].
    Kitamoto K; Hayashi T; Tamada S; Ezaki K; Kawashima H; Sugimura K; Nakatani T
    Hinyokika Kiyo; 2005 Jan; 51(1):33-5. PubMed ID: 15732339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma.
    Graham SD; Walker A; Cox EB; Laszlo J; Berry WR; Paulson DF
    Urology; 1986 Nov; 28(5):404-8. PubMed ID: 3538611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.